Übersetzung für "Das virologische" in Englisch

Close monitoring of patient's virologic response should be exercised.

Virologic response was preserved throughout the study period in both arms.

Irrespective of whether Didanosine is taken with or without food, the virological response is based on the total drug exposure.

Virological response should be frequently monitored in the lamivudine-refractory population and appropriate resistance testing should be performed.

Initiation of treatment should take into account the combinations of mutations which may negatively impact the virological response to APTIVUS, co-administered with low dose ritonavir (see section 5.1).

Virological response should be closely monitored in patients treated with adefovir dipivoxil, with HBV DNA measured every 3 months.

Shortening the treatment duration in patients with genotype 1 and high viral load (HVL) (> 800, 000 IU/ ml) at baseline who become HCV RNA negative at week 4 and remain HCV RNA negative at week 24 should be considered with even more caution since the limited data available suggest that this may significantly negatively impact the sustained virologic response.

Shortening the treatment duration in patients infected with genotype 2 or 3 with HVL (> 800,000 IU/ mL) at baseline who become HCV negative by week 4 should be considered with more caution as this may significantly negatively impact the sustained virological response (see Table 1).

The sustained viral response achieved with 16 weeks of treatment and with 24 weeks of treatment was also examined in a retrospective subgroup analysis of patients who were HCV RNA negative by week 4 and had a LVL at baseline (see Table 10).

Therefore, virological response should be closely monitored in patients with increased dosage interval (see sections 4.2 and 5.2).

Individual tolerability and virological response should be considered when making the dose adjustment (see section 5.2).

Virological response was first observed to decrease when the fold shift exceeded 2.3-fold; whereas virological benefit was not observed when the fold shift exceeded 12-fold.

However, the effect is unlikely to impact virologic outcome and does not warrant a dose adjustment.

The clinical trial data from ART-experienced patients (TITAN trial and the pooled analysis of the POWER 1, 2 and 3 and DUET 1 and 2 trials) showed that virologic response to PREZISTA co-administered with low dose ritonavir was decreased when 3 or more darunavir RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V) were present at baseline or when these mutations developed during treatment.

Initiation of treatment should take into account the combinations of mutations which may negatively impact the virological response to Aptivus, coadministered with low dose ritonavir (see section 5.1).

Sustained virologic response (SVR12), defined as HCV RNA less than LLOQ at 12 weeks after the cessation of treatment, was the primary endpoint to determine the HCV cure rate.

A reduced virological response was observed in patients with viral strains harbouring two or more mutations at HIV protease codons 33, 82, 84 or 90, and not receiving new enfuvirtide.

In virologically stable treatment-experienced adults, emtricitabine, in combination with an NRTI (either stavudine or zidovudine) and a protease inhibitor (PI) or an NNRTI was shown to be non-inferior to lamivudine with respect to the proportion of responders (< 400 copies/ ml) through 48 weeks (77% emtricitabine, 82% lamivudine).

Antiviral activity of Kaletra in patients failing protease inhibitor therapy: the clinical relevance of reduced in vitro susceptibility to lopinavir has been examined by assessing the virologic response to Kaletra therapy, with respect to baseline viral genotype and phenotype, in 56 patients previous failing therapy with multiple protease inhibitors.

The virological responses of HCV monoinfected patients treated with Pegasys monotherapy and with Pegasys and ribavirin combination therapy in relation to genotype and pre-treatment viral load and in relation to genotype, pre-treatment viral load and rapid virological response at week 4 are summarised in Table 7 and Table 8, respectively.

101 HIV-HCV co-infected patients The virological responses of patients treated with Pegasys monotherapy and with Pegasys and ribavirin combination therapy in relation to genotype and pre-treatment viral load for HIV-HCV co- infected patients are summarised below in Table 14.

The virologic and immunologic responses should be monitored to assure these children achieve response to therapy.

Data from the DUET studies suggest that baseline fold change (FC) in EC50 to etravirine was a predictive factor of virologic outcome, with gradually decreasing responses observed above FC 3 and FC 13.

The trial evaluated pharmacokinetics, safety and tolerability, as well as virologic and immunologic responses through 48 weeks.

Virological response to tipranavir with ritonavir therapy has been evaluated using a tipranavirassociated mutation score based on baseline genotype in RESIST-1 and RESIST-2 patients.